WORLDSymposium 2024 New Treatment Award

The WORLDSymposium New Treatment Award for 2024 was presented to Amicus Therapeutics for ipaglucosidase alfa (Pombiliti®) and Chiesi Global Rare Diseases for pegunigalsidase alfa-iwxj (Elfabrio®) and for velmanase alfa-tycv (Lamzede®) More details.

WORLDSymposium 2024 Exhibitors

WORLDSymposium 2024 attracted over 40 Exhibitors offering a highly interactive forum for discussion of lysosomal diseases with international researchers and health care practitioners. More details.

WORLDSymposium 2024 Program

After the presentation of the Innovation Award, the formal scientific sessions of WORLDSymposium 2024 officially begins with presentations on laboratory research for lysosomal disease. Presentations during the Basic Science sessions are designed to improve our understanding or prediction of the phenomena involved in lysosomal pathology at a molecular, cellular, and animal model level in order to forwardly think about diagnosis and treatment of lysosomal conditions. View full program.